Spero Therapeutics Inc (SPRO)
1.16
-0.03
(-2.52%)
USD |
NASDAQ |
Nov 22, 16:00
1.175
+0.02
(+1.29%)
After-Hours: 20:00
Spero Therapeutics Revenue (TTM): 89.86M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 89.86M |
| June 30, 2024 | 105.43M |
| March 31, 2024 | 100.20M |
| December 31, 2023 | 96.74M |
| September 30, 2023 | 71.26M |
| June 30, 2023 | 48.96M |
| March 31, 2023 | 49.07M |
| December 31, 2022 | 48.58M |
| September 30, 2022 | 2.481M |
| June 30, 2022 | 2.107M |
| Date | Value |
|---|---|
| March 31, 2022 | 3.317M |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 0.258M |
| September 30, 2020 | -2.352M |
| June 30, 2020 | -1.704M |
| March 31, 2020 | -1.275M |
| December 31, 2019 | 0.831M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
-2.352M
Minimum
Sep 2020
105.43M
Maximum
Jun 2024
38.36M
Average
25.95M
Median
Revenue (TTM) Benchmarks
| CytomX Therapeutics Inc | 126.62M |
| Johnson & Johnson | 87.70B |
| Arbutus Biopharma Corp | 6.742M |
| Equillium Inc | 45.91M |
| NovaBay Pharmaceuticals Inc | 13.84M |